Stable non progressive deficits with inpatient workup need
Functional decline needing PT and OT planning
Transfer and escalation
Transfer criteria
Need for plasma exchange capability
Suspected severe Guillain Barre syndrome
Rapidly progressive weakness
Need for neurosurgical capability
Imaging evidence of compression
Cauda equina syndrome concern
Discharge criteria
Discharge only when low risk
Stable symptoms without progression over 24 to 48 hours
No bulbar symptoms
Normal respiratory mechanics when measured
Safe ambulation plan
Gait aid provided if needed
Reliable supervision at home
Rapid follow up arranged
Neurology or primary care within 72 hours
Return precautions clearly documented
Treatment
Supportive care and prevention
Supportive bundle
Airway and breathing support
If declining respiratory mechanics, early noninvasive support trial only with close monitoring
If bulbar dysfunction or rapid decline, intubation strategy with experienced operator
Autonomic instability management
Continuous telemetry
Bedside atropine availability for symptomatic bradycardia
Venous thromboembolism prophylaxis
Pharmacologic prophylaxis unless contraindicated
Mechanical prophylaxis when anticoagulation contraindicated
Disease specific immunotherapy
Guillain Barre syndrome therapy
First line immunotherapy
Intravenous immunoglobulin total dose 2 g per kg
0.4 g per kg per day for 5 days
Infusion reaction monitoring
Thrombosis risk assessment
Plasma exchange
4 exchanges over 7 to 14 days
Typical exchange volume 40 to 50 mL per kg per session
Central access complication monitoring
Timing principles
Benefit greatest when started within 2 weeks of onset
Consider within 4 weeks for ongoing progression
Corticosteroids
Not recommended as monotherapy in Guillain Barre syndrome
No functional outcome benefit in trials
Neuropathic pain control
Pain management ladder
First line adjuvants
Gabapentin
100 to 300 mg PO at bedtime
Titrate by 100 to 300 mg per dose every 1 to 2 days as tolerated
Typical target 900 to 1800 mg per day in divided doses
Pregabalin
25 to 75 mg PO twice daily
Titrate every 3 to 7 days
Maximum 600 mg per day
Duloxetine
30 mg PO daily
Increase to 60 mg PO daily after 1 week if tolerated
Avoid in severe hepatic disease
Second line options
Amitriptyline
10 to 25 mg PO at bedtime
Increase by 10 to 25 mg weekly as tolerated
Anticholinergic adverse effect monitoring
Topical lidocaine 5 percent patch
Up to 12 hours on then 12 hours off
Local skin irritation monitoring
Short term opioid rescue
Hydromorphone
0.2 to 0.5 mg IV every 2 to 3 hours as needed
Respiratory depression monitoring
Oxycodone
2.5 to 5 mg PO every 4 to 6 hours as needed
Constipation prophylaxis
Etiology targeted therapy
Deficiency replacement
Thiamine replacement when deficiency risk
100 mg IV daily
Transition to 100 mg PO daily when stable intake
Vitamin B12 replacement when deficient
1000 micrograms IM weekly for 4 weeks
Then 1000 micrograms IM monthly
Toxic exposure management
Offending agent cessation
Chemotherapy coordination with oncology
Neurotoxic antibiotic discontinuation plan
Chelation only with specialist input for confirmed heavy metal toxicity
Clinical toxicology consultation
Occupational exposure mitigation
Vasculitic neuropathy management
High suspicion pathway
Rheumatology consultation
Tissue diagnosis planning when feasible
Immunosuppression decisions specialist led
Glucocorticoids and steroid sparing agent selection
Infection prophylaxis planning
Rehabilitation and recovery
Function restoration
Early PT and OT involvement
Range of motion to prevent contractures
Assistive device fitting
Dysphagia precautions
Speech language evaluation
Aspiration prevention strategies
Special Populations
Pregnancy
Pregnancy considerations
Diagnostic adjustments
MRI preferred over CT when feasible for spine evaluation
Ionizing radiation minimization strategy
Therapy considerations
IVIG acceptable when indicated for Guillain Barre syndrome
Plasma exchange feasible with obstetric and ICU coordination
Maternal fetal monitoring triggers
Autonomic instability
Respiratory compromise
Geriatric
Older adult considerations
Higher complication risk
Aspiration pneumonia risk with bulbar dysfunction
Delirium risk with sedating analgesics
Medication safety
Lower starting doses for gabapentinoids
Avoid tricyclics when high fall risk or conduction disease
Alternate diagnoses prevalence
Spinal stenosis and radiculopathy overlap
Nutritional deficiency risk with low intake
Pediatrics
Pediatric considerations
Weight based respiratory thresholds
Age appropriate forced vital capacity interpretation
Close monitoring with rapid progression
Pediatric Guillain Barre syndrome therapy
IVIG 2 g per kg total dose
Typically divided over 2 to 5 days per local protocol
Etiology differences
Post infectious patterns common
Toxic ingestion screening when unexplained
Background
Epidemiology
Epidemiology facts
Guillain Barre syndrome incidence
Approximately 1 to 2 per 100000 per year
Incidence increases with age
Common acute neuropathy categories in ED
Immune mediated polyradiculoneuropathy
Toxic and metabolic neuropathies
Prognosis overview
Majority recover ambulation over months
Subset require mechanical ventilation
Pathophysiology
Mechanisms
Demyelinating polyradiculoneuropathy
Immune attack on peripheral myelin
Conduction slowing and block
Axonal variants
Immune mediated axonal injury
Slower recovery with severe deficits
Dysautonomia mechanisms
Small fiber involvement
Labile sympathetic and parasympathetic output
Therapeutic Considerations
Treatment principles
IVIG and plasma exchange efficacy in Guillain Barre syndrome
Faster recovery when started early
Similar efficacy between modalities in many studies
Combination therapy
Routine sequential plasma exchange plus IVIG not standard
Specialist directed exceptions only
Steroids in Guillain Barre syndrome
Lack of benefit for functional recovery
Adverse effect burden
Respiratory failure prevention
Serial mechanics superior to pulse oximetry alone
Bulbar dysfunction as early intubation predictor
Patient Discharge Instructions
copy discharge instructions
Discharge instructions for acute peripheral neuropathy
Diagnosis uncertainty and follow up plan
Neurology or primary care follow up within 72 hours
Lab and test results review plan
Return to ED immediately for red flags
New or worsening weakness
Trouble breathing
Trouble swallowing or choking
New facial droop or trouble speaking
New fainting or severe dizziness
Chest pain or palpitations
New loss of bladder or bowel control
Safety and function
No driving until cleared if weakness or numbness affects pedals
Fall prevention at home
Medication counseling
Sedation risk with gabapentin or pregabalin
Avoid alcohol with sedating medications
References
Clinical guidelines and consensus
Guideline sources
American Academy of Neurology practice parameter for Guillain Barre syndrome immunotherapy
IVIG or plasma exchange recommended for non ambulatory patients
Corticosteroids not recommended as monotherapy
European Federation of Neurological Societies and Peripheral Nerve Society guidance on GBS diagnosis and management
Respiratory and autonomic monitoring emphasis
Early immunotherapy for progressive weakness
Evidence based sources
Key evidence
Randomized trials and meta analyses comparing IVIG and plasma exchange in Guillain Barre syndrome
Similar functional outcomes in many comparisons
Earlier treatment associated with better recovery trajectories
Cohort studies on dysautonomia complications in Guillain Barre syndrome
Arrhythmia risk support for telemetry
Labile blood pressure risk support for ICU monitoring
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.